Thryv Therapeutics Inc. Announces the Presentation of Scientific Data for Its Novel SGK1 inhibitors at American Heart Association and San Antonio Breast Cancer Symposium
/PRNewswire/ - Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndrome (LQTS) via SGK1...
Source: prnewswire.com